Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression

Biomaterials

Volumn 34, Issue 15, 2013, Pages 3912-3923

  Wei, Wei ^a   Lv, Pi Ping ^a,b   Chen, Xiao Ming ^a,b   Yue, Zhan Guo ^a,b   Fu, Qiang ^a,c   Liu, Shi Ying ^a,b   Yue, Hua ^a   Ma, Guang Hui ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Chitosan; Drug delivery; Nanoparticles; Paclitaxel; SiRNA

Indexed keywords

ANTI-TUMOR ACTIVITIES; CHEMOTHERAPEUTIC DRUGS; CLINICAL APPLICATION; ENZYMATIC DEGRADATION; INTRACELLULAR UPTAKE; PACLITAXEL; SIRNA; TELOMERASE REVERSE TRANSCRIPTASE;

CHITOSAN; CHLORINE COMPOUNDS; DRUG DELIVERY; NANOPARTICLES; TUMORS;

GENE THERAPY;

CHITOSAN; NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENZYMATIC DEGRADATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ABSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CARBOCYANINES; CARCINOMA, LEWIS LUNG; CELL DEATH; CELL PROLIFERATION; CHITOSAN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FLOW CYTOMETRY; GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMANS; INTRACELLULAR SPACE; MALE; MICE; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PERMEABILITY; QUATERNARY AMMONIUM COMPOUNDS; RNA, SMALL INTERFERING; TELOMERASE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874996157     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.030     Document Type: Article

References (28)

1. Li X., Chen Y., Wang M., Ma Y., Xia W., Gu H. A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013, 34(4):1391-1401.
2. Bossi G., Marampon F., Maor-Aloni R., Zani B., Rotter V., Oren M., et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008, 7(12):1870-1879.
3. Shay J.W., Wright W.E. Telomerase: a target for cancer therapeutics. Cancer Cell 2002, 2(4):257-265.
4. Cerone M.A., Londoño-Vallejo J.A., Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther 2006, 5(7):1669-1675.
5. Kyo S., Takakura M., Inoue M. Telomerase activity in cancer as a diagnostic and therapeutic target. Histol Histopathol 2000, 15(3):813-824.
6. Gellert G.C., Jackson S.R., Dikmen Z.G., Wright W.E., Shay J.W. Telomerase as a therapeutic target in cancer. Drug Discov Today Dis Mech 2005, 2(2):159-164.
7. Zhang Z., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006, 12(16):4933-4939.
8. Xue H.Y., Wong H.L. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011, 5(9):7034-7047.
9. Butz K., Ristriani T., Hengstermann A., Denk C., Scheffner M., Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22(38):5938-5945.
10. Saydam O., Glauser D.L., Heid I., Turkeri G., Hilbe M., Jacobs A.H., et al. Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther 2005, 12(5):803-812.
11. Takei Y., Kadomatsu K., Goto T., Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006, 107(4):864-873.
12. Zhu C.H., Jung S., Luo S.B., Meng F.H., Zhu X.L., Park T.G., et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010, 31(8):2408-2416.
13. Nuhn L., Hirsch M., Krieg B., Koynov K., Fischer K., Schmidt M., et al. Cationic nanohydrogel particles as potential siRNA carriers for cellular delivery. ACS Nano 2012, 6(3):2198-2214.
14. Cao N., Cheng D., Zou S.Y., Ai H., Gao J.M., Shuai X.T. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011, 32(8):2222-2232.
15. Wang Y., Gao S.J., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5(10):791-796.
16. Chaturvedi K., Ganguly K., Kulkarni A.R., Kulkarni V.H., Nadagouda M.N., Rudzinski W.E., et al. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opin Drug Deliv 2011, 8(11):1455-1468.
17. Xiao Y., Jaskula-Sztul R., Javadi A., Xu W., Eide J., Dammalapati A., et al. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012, 4(22):7185-7193.
18. Sun T.M., Du J.Z., Yao Y.D., Mao C.Q., Dou S., Huang S.Y., et al. Simultaneous delivery of siRNA and paclitaxel via a " two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5(2):1483-1494.
19. Lv P.P., Wei W., Yue H., Yang T.Y., Wang L.Y., Ma G.H. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration. Biomacromolecules 2011, 12(12):4230-4239.
20. Wu J., Wei W., Wang L.Y., Su Z.G., Ma G.H. A thermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system. Biomaterials 2007, 28(13):2220-2232.
21. Lv P.P., Ma Y.F., Yu R., Yue H., Ni D.Z., Wei W., et al. Targeted delivery of insoluble cargo (paclitaxel) by PEGylated chitosan nanoparticles grafted with Arg-Gly-Asp (RGD). Mol Pharm 2012, 9(6):1736-1747.
22. Lv P.P., Wei W., Gong F.L., Zhang Y.L., Zhao H.Y., Lei J.D., et al. Preparation of uniformly sized chitosan nanospheres by a premix membrane emulsification technique. Ind Eng Chem Res 2009, 48(19):8819-8828.
23. Wei W., Wang L.Y., Yuan L., Wei Q., Yang X.D., Su Z.G., et al. Preparation and application of novel microspheres possessing autofluorescent properties. Adv Funct Mater 2007, 17(16):3153-3158.
24. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266(5193):2011-2015.
25. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W.Y. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009, 30(19):3297-3306.
26. Pittella F., Zhang M.Z., Lee Y., Kim H.J., Tockary T., Osada K., et al. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 2011, 32(11):3106-3114.
27. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119(3):661-673.
28. Yue Z.G., Wei W., Lv P.P., Yue H., Wang L.Y., Su Z.G., et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules 2011, 12(7):2440-2446.